MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5 (MONITOR-CKD5)
An International, Prospective, Open-label, Multicenter, Pharmacoepidemiological Study to Determine Predictors of Clinical Outcomes in Haemodialysis Patients With Anaemia Treated With Biosimilar Epoetin Alfa
Sponsor: Hexal AG
Listed as NCT01121237, this observational or N/A phase trial focuses on Anaemia and Chronic Kidney Disease and remains completed. Sponsored by Hexal AG, it has been updated 7 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Feb 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hexal AG
- Sandoz
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Acireale, Italy , Ajaccio, France , Alsfeld, Germany , Altamura, Italy , Arenzano, Italy , Arezzo, Italy , Arnstadt, Germany , Bad Neustadt A. D. Saale, Germany , Bassum, Germany , Berlin, Germany and 85 more locations